In This Section

Cancer Discovery to Publish COVID-19 and Cancer Consortium Data on Final Day of AACR COVID-19 and Cancer Meeting

PHILADELPHIA – Cancer Discovery, a journal of the American Association for Cancer Research, will publish a COVID-19 and Cancer Consortium (CCC19) study analyzing the use of COVID-19 treatments and clinical outcomes among patients with cancer on Wednesday, July 22, at 1:45 p.m. ET.

CCC19 is a consortium of more than 100 cancer centers and other organizations who have come together to collect data about patients with cancer who have been diagnosed with COVID-19. The goal of the consortium is to collect and disseminate prospective, granular, uniformly organized information on this patient population at scale and as rapidly as possible.

In this study, researchers led by corresponding author and CCC19 Steering Committee member Jeremy L. Warner, MD, Vanderbilt-Ingram Cancer Center, evaluated data from more than 2,000 individuals to examine the impact of COVID-19 treatments on 30-day all-cause mortality and understand factors associated with receipt of treatment.

Reporters may request an embargoed copy of the paper by contacting Julia Gunther at [email protected] or Matthew Burns at [email protected].

The release of the paper will coincide with the final day of the AACR Virtual Meeting: COVID-19 and Cancer, a three-day event that featured the latest basic, clinical, and epidemiologic research related to COVID-19 and cancer, and discussion of how this unprecedented situation has impacted biomedical research, cancer care, vaccine development, and drug repurposing.

Specifically, the paper will be published at the beginning of the meeting session “Epidemiology and Registries of COVID-19 and Cancer,” which includes a related presentation by CCC19 Steering Committee member Brian I. Rini, MD, Vanderbilt-Ingram Cancer Center, titled “Understanding the impact of COVID in cancer patients through the COVID-19 and Cancer (CCC-19) and other COVID consortiums.”

Reporters may register for the meeting by contacting Kathleen Venango at [email protected].